.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,231,851

« Back to Dashboard

Details for Patent: 6,231,851

Title: Methods and compositions for the dry powder formulation of interferons
Abstract:According to the present invention, methods and compositions are provided for spray-dried, interferon-based dry powder compositions, particularly interferon-beta. The compositions are useful for treating conditions in humans that are responsive to treatment with interferons. In particular, the methods of the present invention rely on spray drying to produce stable, high-potency dry powder formulations of interferons, including but not limited to IFN-beta. Surprisingly, it has been found that IFN can be prepared in high potency, dry powder formulations by spray drying. Such dry powder formulations find particular utility in the pulmonary delivery of IFN.
Inventor(s): Platz; Robert M. (Half Moon Bay, CA), Kimura; Shigenobu (Ako-gun, JP), Satoh; Yu-ichiro (Kita-ku, JP), Foster; Linda C. (Mountain View, CA)
Assignee: Inhale Therapeutic Systems (San Carlos, CA)
Filing Date:Jul 14, 1997
Application Number:08/737,724
Claims:1. A spray-dried, bioactive interferon-.beta.-based dry powder composition, which, when administered pulmonarily, is rapidly systemically absorbed, comprising a therapeutically effective amount of an interferon-.beta. in combination with a pharmaceutically acceptable carrier.

2. The composition of claim 1, wherein the composition is substantially free from penetration enhancers.

3. The composition of claim 2, wherein the carrier comprises human serum albumin.

4. The composition of claim 3, wherein the carrier further comprises a carbohydrate bulking agent.

5. The composition of claim 4, wherein the carrier is mannitol.

6. The composition of claim 4, wherein the carrier is raffinose.

7. The composition of claim 1, wherein about 95% of the mass of the dry powder composition has a particle size of less than 10 .mu.m.

8. The composition of claim 7, wherein about 80% of the mass of the dry powder composition has a particle size of less than 5 .mu.m.

9. The composition of claim 1, wherein the interferon-.beta. is naturally occurring.

10. A unit dosage form for pulmonary delivery of interferon-.beta., comprising a unit dosage receptacle containing the dry powder composition of claim 1.

11. The unit dosage form of claim 10, wherein the carrier comprises human serum albumin, the composition is substantially free from penetration enhancers and about 95% of the mass of the dry powder composition has a particle size of less than about 10 .mu.m.

12. A method of treating a disease state responsive to treatment by interferon-.beta., comprising pulmonarily administering to a subject in need thereof a physiologically effective amount of a spray-dried, bioactive interferon-.beta.-based dry powder composition comprising a therapeutically effective amount of an interferon-.beta. in combination with a pharmaceutically acceptable carrier, wherein upon said administering, said interferon-.beta. is rapidly systemically absorbed, thereby treating the disease.

13. The method of claim 12, wherein the carrier comprises human serum albumin and a carbohydrate bulking agent, the composition is substantially free from penetration enhancers and about 95% of the mass of the dry powder composition has a particle size of less than about 10 .mu.m.

14. A method for aerosolizing a spray-dried, bioactive interferon-.beta.-based dry powder comprising:

dispersing an amount of the powder composition of claim 1 in a gas stream to form an aerosol, and

capturing the aerosol in a chamber for subsequent inhalation by a patient.

15. The method of claim 14, wherein the carrier comprises human serum albumin and a carbohydrate bulking agent, the composition is substantially free from penetration enhancers and about 95% of the mass of the dry powder composition has a particle size of less than about 10 .mu.m.

16. A method for preparing the bioactive, spray-dried, interferon-.beta.-based dry powder composition claim 1, comprising spray-drying an aqueous solution of the interferon-.beta. and the carrier under conditions to provide a respirable dry powder, which, when administered pulmonarily is rapidly systemically absorbed.

17. The method of claim 16 wherein the composition is substantially free from penetration enhancers.

18. The method of claim 17, wherein the carrier comprises human serum albumin.

19. The method of claim 18, wherein the carrier further comprises a carbohydrate bulking agent.

20. The method of claim 19, wherein the bulking agent is mannitol.

21. The method of claim 19, wherein the bulking agent is raffinose.

22. The method of claim 16, wherein 95% of the mass of the spray-dried composition has a particle size less than 10 .mu.m.

23. The spray-dried, bioactive interferon-.beta.-based dry powder composition claim 9, wherein (i) said carrier comprises human serum albumin or human serum albumin and a carbohydrate bulking agent, (ii) the composition is substantially free from penetration enhancers, and (iii )about 95% of the mass of the dry powder composition has a particle size of less than 10 .mu.m.

24. The composition of claim 23, wherein the bulking agent is mannitol.

25. The composition of claim 23, wherein the bulking agent is raffinose.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc